CTIS2024-514330-20-00进行中（未招募）1 期
A single-center, self-controlled, single-arm pilot clinical trial to assess the effect of lamivudine (3TC) on neurocognitive impairment biomarkers and type-I IFN (interferon)-stimulated genes in the plasma of patients with Mild Cognitive Impairment (MCI) - LAMIFERO
Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia0 个研究点目标入组 25 人开始时间: 2024年5月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1.Male or female participants 55 to 90 years of age (both inclusive) at the time of signing the informed consent., 10.A male participant must agree to use a highly effective contraception method during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period., 11.A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use a highly effective contraception method during the treatment period and for at least 3 months after the last dose of study treatment., 12.Written informed consent provided by participant (or legal representative) and caregiver prior to any study-specific procedures., 2.Diagnosis of prodromal AD: MCI due to AD according to National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria as determined by a neurologist, geriatrician, psychiatrist, or clinician approved by the Sponsor or designee., 3.Clinical Dementia Rating (CDR)-Global Score of 0.5, 4.Imaging studies (MRI or CT) within 2 years prior to screening that exclude secondary causes of dementia., 5.Documented confirmation of AD diagnosis by positive CSF AD signature or positive amyloid-PET. CSF AD positivity established with low levels of CSF Aß1-42 or CSF Aß1-42/Aß1-40 and high levels of p-Tau. A CSF examination performed within 12 months prior to screening is allowed. A positive amyloid-PET is defined as abnormal deposits of amyloid in the PET imaging., 6.If receiving an approved medication for AD (i.e., donepezil, galantamine, rivastigmine, memantine, or memantine/donepezil combination product), must be on the medication with a stable dose for at least 4 weeks before the screening visit (dosing should remain stable throughout the study)., 7.If receiving an OTC supplement for cognition (e.g., gingko biloba, omega-3 polyunsaturated fatty acid, vitamin E, curcumin), must not be exceeding the recommended dose and be at stable dose for at least 4 weeks prior to screening visit., 8.Able to visit the study center and undergo cognitive, functional, and other tests specified in the protocol., 9.In the event that the participant requires a caregiver, the caregiver: a.Agrees to accompany the participant to all study visits and able to supervise the participant’s compliance with the study procedures and provide detailed information about the participant. b.Either lives with the participant or sees the participant on average for = 1 hour/day = 3 days/week, or in the Investigator’s opinion, the extent of contact is sufficient to provide meaningful assessment of changes in participant behavior and function over time and provide information on safety and tolerability. c.Can read, understand, and speak the designated language at the study center. d.Caregiver must be cognitively able to fulfill the requirements of the study.
排除标准
- •1.Possible, probable, or definite vascular dementia according to the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l’Enseignement en Neurosciences (NINDS-AIREN) criteria., 18.Resides in a moderate to high dependency continuous care facility (residence in low grade assisted living facility where there is sufficient autonomy to permit valid evaluation of activities of daily living is allowed)., 19.Any other reason that in the opinion of the investigator would make the participant ineligible to participate or to complete this study., 2.Evidence of significant abnormality that would suggest another potential etiology for dementia (e.g., evidence of cerebral contusion, encephalomalacia, aneurysm, vascular malformation, > 10 microhemorrhages, macrohemorrhage, single infart > 1 cm3)., 20.Refrain from donating blood or blood products from the screening visit until 3 months after the EOS/ET visit., 3.Other central nervous system diseases that may cause cognitive impairment (e.g., cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington’s disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease)., 4.Concurrent or history of clinically significant psychiatric conditions (e.g., schizophrenia or bipolar affective disorder) that in the Investigator’s opinion prevents the participant from participating or is likely to confound interpretation of drug effect or affect cognitive assessments., 5.Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results that are thought to contribute to the severity of dementia or cause dementia. Participants may be enrolled if in the Investigator’s medical judgment, the abnormal laboratory values are not the cause of the cognitive symptoms., 6.History of known or suspected seizures including febrile seizures (excluding self-limited childhood febrile seizures), a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained., 7.Acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or any medical condition that may interfere with the completion of the clinical study., 8.Known allergies, hypersensitivity, or intolerance to lamivudine or similar products or excipients., 10.Concurrent malignancies or invasive cancers diagnosed within the past 3 years except for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non-metastatic prostate càncer., 9.History of alcohol, substance abuse or dependence as per DSM-V criteria (except nicotine dependence) within the last 3 years., 21. Positive blood screen for Human Immunodeficiency Virus (HIV-1 and 2)., 11.Sexually active WOCBP or man capable of fathering a child who do not consent to using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom, or diaphragm, an injectable or inserted contraceptive) during the study and for 3 months after the last dose of study treatment., 12.Use of anxiolytics, narcotics, or sleep aids in a manner that would interfere with cognitive testing, in the opinion of the investigator. Atypical antipsychotics may be used at the discretion of the Investigator. Tricyclic antidepressants and monoamine oxidase (MAO) inhibitors may be used at the discretion of the inv
研究者
相似试验
招募中
不适用
A study of providing adult smokers, who smoke at least one cigarette per day, the opportunity to sample a range of nicotine replacement therapies (NRTs) in everyday non-medical community locations, to determine if this is acceptable to smokers, and whether it increases their motivation to quit smoking, encourages them to use NRTs, and helps them to quit smoking and remain abstinent for three months.ACTRN12614000054617Ministry of Health1,000
招募中
Unknown
Evaluation of the NaviFUS System in drug resistant epilepsyDrug Resistant Temporal Lobe EpilepsyNeurological - EpilepsyTemporal Lobe EpilepsyACTRN12623000382673Genovate-NaviFUS (Australia) Pty Ltd18
终止
不适用
Instylla Hydrogel Embolic System Pilot Study For Patients Requiring Transcatheter Embolization of Vascular BleedsACTRN12620000349943Instylla Inc2
已完成
1 期
A prospective, single arm, single centre pilot trial to establish the safety and efficacy of the Oventus device to treat mild to moderate obstructive sleep apnoea and snoring.Mild to moderate obstructive sleep apnoeaSnoringRespiratory - Sleep apnoeaACTRN12615000028505Oventus Pty Ltd30
进行中（未招募）
1 期
Eine offene, nicht randomisierte, einarmige Pilotstudie zur Beurteilung der Wirksamkeit von Erythropoetin bei Friedreich Ataxie.Die Friedreich Ataxie (FRDA) ist eine autosomal-rezessiv vererbte, progressive neurodegenerative Erkrankung, die mit einer Inzidenz von rund 1:50.000 auftritt. Es handelt sich dabei um die am häufigsten vorkommende Ataxie beim Menschen. Sie manifestiert sich klinisch initial als spinozerebelläre Ataxie, im weiteren Krankheitsverlauf tritt meist eine hypertrophe Kardiomyopathie hinzu, deren Komplikationen häufig für den frühen Tod der Patienten verantwortlich sind.EUCTR2005-005938-12-ATDr. Sylvia Boesch12